Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

US9512124B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9512124-B2
Application numberUS-201514874513-A
CountryUS
Kind codeB2
Filing dateOct 5, 2015
Priority dateOct 6, 2014
Publication dateDec 6, 2016
Grant dateDec 6, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided herein are Aminopurine Compounds having the following structures: wherein R 1 , R 2 , and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound of formula (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer or enantiomer thereof, wherein: R 1 is substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, or substituted or unsubstituted non-aromatic heterocyclyl; R 2 is H or substituted or unsubstituted C 1-3 alkyl; R 3 is phenyl, substituted with one or more halogen, optionally further substituted with one or more substitutents independently selected from substituted or unsubstituted C 1-3 alkyl, CN, and —OR′, wherein each R′ is independently substituted or unsubstituted C 1-3 alkyl; wherein when an alkyl group is substituted, it is substituted with a substituent selected from the group consisting of chloro; iodo; bromo; fluoro; alkyl; hydroxyl; alkoxy; alkoxyalkyl; amino; alkylamino; carboxy; nitro; cyano; thiol; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino; phosphonate; phosphine; thiocarbonyl; sulfinyl; sulfone; sulfonamide; acyl; ester; urea; urethane; oxime; hydroxyl amine; alkoxyamine; aryloxyamine, aralkoxyamine; N-oxide; hydrazine; hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; B(OH) 2 , and O(alkyl)aminocarbonyl; wherein when a group other than alkyl is substituted, it is substituted with a substituent selected from the group consisting of chloro; iodo; bromo; fluoro; alkyl; hydroxyl; alkoxy; alkoxyalkyl; amino; alkylamino; carboxy; nitro; cyano; thiol; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino; phosphonate; phosphine; thiocarbonyl; sulfinyl; sulfone; sulfonamide; acyl; ester; urea; urethane; oxime; hydroxylamine; alkoxyamine; aryloxyamine; aralkoxyamine; N-oxide; hydrazine; hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; oxo; B(OH) 2 , O(alkyl)aminocarbonyl; cycloalkyl, which may be monocyclic or fused or non-fused polycyclic, or a heterocyclyl, which may be monocyclic or fused or non-fused polycyclic; monocyclic or fused or non-fused polycyclic aryl or heteroaryl; aryloxy; aralkyloxy; heterocyclyloxy; and heterocyclylalkoxy; and provided the compound is not 4[2-[(1-methylethyl)amino]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-9 -yl]-cis-cyclohexanecarboxamide, or 4-[8-[(2,4-difluorophenyl)amino]-2-[(trans-4-hydroxycyclohexyl)amino]-9H-purin-9-yl]-cis-cyclohexanecarboxamide. 2. The compound of claim 1 , wherein R 1 is substituted or unsubstituted C 1-8 alkyl. 3. The compound of claim 2 , wherein R 1 is substituted or unsubstituted methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 2-methylpentyl, 3-methylpentyl, isopentyl, or neopentyl. 4. The compound of claim 2 , wherein R 1 is substituted with one or more substituents independently selected from halogen and OR, wherein each R is independently H or substituted or unsubstituted C 1-3 alkyl. 5. The compound of claim 2 , wherein R 1 is substituted with one or more substituents independently selected from F, OH, and OCH 3 . 6. The compound of claim 2 , wherein R 1 is ethyl, isopropyl, isobutyl, tert-butyl, CH 2 CH 2 F, CH 2 CHF 2 , CH 2 CF 3 , CH 2 CH(CH 3 )OH, CH 2 CH(CH 3 )OCH 3 , CH(CH 3 )CH 2 OH, CH(CH 3 )CH 2 OCH 3 , CH 2 C(F 2 )CH 2 OH, CH 2 C(F 2 )CH 2 OCH 3 , CH(CF 3 )CH 2 OH, CH(CF 3 )CH 2 OCH 3 , CH(CH 2 OH)CH 2 CH 3 , CH(CH 2 OCH 3 )CH 2 CH 3 , CH 2 C(CH 3 ) 2 CH 2 OH, or CH 2 C(CH 3 ) 2 CH 2 OCH 3 . 7. The compound of claim 2 , wherein R 1 is isopropyl, isobutyl, tert-butyl, CH 2 CF 3 , CH 2 CH(CH 3 )OH, CH(CH 3 )CH 2 OH, CH(CH 3 )CH 2 OCH 3 , CH 2 C(F 2 )CH 2 OH, CH(CF 3 )CH 2 OH, CH(CH 2 OH)CH 2 CH 3 , or CH 2 C(CH 3 ) 2 CH 2 OH. 8. The compound of claim 1 , wherein R 1 is substituted or unsubstituted cycloalkyl. 9. The compound of claim 8 , wherein R 1 is substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl. 10. The compound of claim 8 , wherein R 1 is substituted with one or more substituents independently selected from halogen, OR, SO 2 R′, substituted or unsubstituted C 1-3 alkyl, and substituted or unsubstituted heterocyclyl, wherein each R is independently H or substituted or unsubstituted C 1-3 alkyl, and each R′ is independently substituted or unsubstituted C 1-3 alkyl. 11. The compound of claim 8 , wherein R 1 is substituted with one or more substituents independently selected from F, OH, OCH 3 , SO 2 CH 3 , methyl, and a substituted or unsubstituted 5-membered heterocyclyl. 12. The compound of claim 11 , wherein the 5-membered heterocylyl is pyrroldinedionyl, or oxadiazolyl. 13. The compound of claim 8 , wherein R 1 is cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, optionally substituted with one or more substituents independently selected from F, OH, OCH 3 , SO 2 CH 3 , methyl, pyrrolidinedionyl, and oxadiazolyl. 14. The compound of claim 1 , wherein R 1 is substituted or unsubstituted cycloalkylalkyl. 15. The compound of claim 14 , wherein R 1 is substituted or unsubstituted (C 1-3 alkyl)-(C 1-8 cycloalkyl). 16. The compound of claim 14 , wherein R 1 is substituted or unsubstituted CH 2 -cyclopropyl, CH 2 -cyclobutyl, CH 2 -cyclopentyl, CH 2 -cyclohexyl, or CH 2 -cycloheptyl. 17. The compound of claim 14 , wherein R 1 is substituted with one or more substituents independently selected from (C 1-3 alkyl)OR or OR, wherein each R is independently H or substituted or unsubstituted C 1-3 alkyl. 18. The compound of claim 14 , wherein R 1 is CH 2 -cyclopropyl, CH 2 -cyclobutyl, CH 2 -cyclopentyl, or CH 2 -cyclohexyl, optionally substituted with one or more CH 2 OH or OH. 19. The compound of claim 1 , wherein R 1 is substituted or unsubstituted non-aromatic heterocyclyl. 20. The compound of claim 19 wherein R 1 is substituted or unsubstituted oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydro-thiopyrandioxide, piperidyl, oxepanyl, or oxaspiroheptyl. 21. The compound of claim 19 wherein R 1 is substituted with one or more substituents independently selected from halogen, OR, SO 2 R 4 , C(═O)R 5 , C(═O)OR 6 , C(═O)NRR 7 , substituted or unsubstituted C 1-3 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted or alkylaryl, wherein each R is independently H or substituted or unsubstituted C 1-3 alkyl; R 4 is substituted or unsubstituted C 1-3 alkyl, or substituted or unsubstituted aryl; R 5 is substituted or unsubstituted C 1-3 alkyl; R 6 is substituted or unsubstituted C 1-6 alkyl; and R 7 is substituted or unsubstituted C 1-3 alkyl, or substituted or unsubstituted aryl. 22. The compound of claim 19 wherein R 1 is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydro-thiopyrandioxide, piperidyl, oxepanyl, or oxaspiroheptyl, optionally substituted with one or more substituents independently selected from F, OH, SO 2 CH 3 , SO 2 -tosyl, C(═O)CH 3 , C(═O)OCH 3 , C(═O)O-tert-butyl, C(═O)O-isopropyl, C(═O)NHCH 3 , C(═O)NH-phenyl, methyl, ethyl, isopropyl, CH 2 OH, phenyl, pyridyl, or benzyl. 23. The compound of claim 1 , wherein R 2 is H. 24. The compound of claim 1 , wherein R 2 is CH 3 . 25. The compound of claim 1 , wherein R 3 is ortho-halogen substituted phe

Assignees

Inventors

Classifications

  • C07D473/32Primary

    Nitrogen atom · CPC title

  • A61K31/52Primary

    Purines, e.g. adenine · CPC title

  • not condensed and containing further heterocyclic rings, e.g. timolol · CPC title

  • Antineoplastic agents · CPC title

  • Three nitrogen atoms · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9512124B2 cover?
Provided herein are Aminopurine Compounds having the following structures: wherein R 1 , R 2 , and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
Who is the assignee on this patent?
Signal Pharm Llc
What technology area does this patent fall under?
Primary CPC classification C07D473/32. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).